2 hours ago
Description
(AWP Alliance News) - Natera announced new data on its Signatera test in resected stage 1-3 non-small cell lung cancer, presented at the IASLC 2026 World Conference on Lung Cancer in Seoul. The analysis, described as the largest lung cancer MRD dataset reported to date, found that an early post-surgery Signatera-positive result was linked to a higher likelihood of recurrence and shorter survival.
The study also indicated that patients who turned positive during surveillance faced a materially higher risk of recurrence or death. The findings support broader use of Signatera monitoring to guide post-surgical treatment decisions in early-stage lung cancer.
https://www.businesswire.com/news/home/20260918220514/en/
Disclaimer: This news brief was created using generative artificial intelligence. Natera Inc. published the original content used to generate this news brief via Business Wire on September 18, 2026, and is solely responsible for the information contained therein.
